We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

CbdMD Inc (YCBD) USD0.001

Sell:$0.43 Buy:$0.50 Change: $0.0176 (3.96%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.0176 (3.96%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
Change: $0.0176 (3.96%)
Market closed |  Prices as at close on 24 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

cbdMD, Inc. produces and distributes spectrum cannabidiol (CBD) products and spectrum CBD products. The Company owns and operates the CBD brands, including cbdMD, Paw CBD and cbdMD Botanicals. cbdMD includes approximately 130 SKUs of premium CBD products, including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, and CBD sleep aids. Paw CBD includes approximately 45 SKUs of veterinarian-formulated products, including tinctures, chews, topicals products in varying strengths and formulas. cbdMD Botanicals brand of beauty and skincare products features approximately 15 SKUs, including facial oil and serum, toners, moisturizers, clear skin, facial masks, exfoliants and body care. The Company operates through seven segments: staff related expenses, accounting and legal expenses, professional outside services, travel and entertainment expenses, rent, business insurance, and non-cash stock compensation expense.

Contact details

8845 Red Oak Blvd
United States
+1 (704) 4453060

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$24.60 million
Shares in issue:
59.36 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Kevin Macdermott
  • T. Ronan Kennedy
    Chief Financial Officer, Chief Operating Officer
  • Francisco Mangual
    Senior Vice President - Sales
  • David Johnson
    Senior Vice President - Business Development
  • Matthew Coapman
    Chief Marketing Officer
  • Sibyl Swift
    Vice President - Scientific and Regulatory Affairs
  • Lance Blundell
    General Counsel

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.